Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $86.55 in the prior trading day, Blueprint Medicines Corp (NASDAQ: BPMC) closed at $85.99, down -0.65%. In other words, the price has decreased by -$0.65 from its previous closing price. On the day, 0.7 million shares were traded. BPMC stock price reached its highest trading level at $87.0 during the session, while it also had its lowest trading level at $84.27.
Ratios:
Our goal is to gain a better understanding of BPMC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.71. In the meantime, Its Debt-to-Equity ratio is 2.31 whereas as Long-Term Debt/Eq ratio is at 1.95.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on May 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $140.
On May 06, 2024, Leerink Partners Upgraded its rating to Market Perform which previously was Underperform and also upped its target price recommendation from $50 to $97.
Oppenheimer Upgraded its Perform to Outperform on October 27, 2023, while the target price for the stock was maintained at $85.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 09 ’24 when Albers Jeffrey W. bought 19,702 shares for $85.57 per share.
Landsittel Michael sold 4,409 shares of BPMC for $419,869 on Aug 15 ’24. The CHIEF FINANCIAL OFFICER now owns 67,208 shares after completing the transaction at $95.23 per share. On Aug 15 ’24, another insider, MICHAEL LANDSITTEL, who serves as the Officer of the company, bought 4,409 shares for $95.23 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5482550272 and an Enterprise Value of 5423823360. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.02 while its Price-to-Book (P/B) ratio in mrq is 16.96. Its current Enterprise Value per Revenue stands at 14.95 whereas that against EBITDA is -15.807.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $43.89. The 50-Day Moving Average of the stock is -16.25%, while the 200-Day Moving Average is calculated to be -8.05%.
Shares Statistics:
The stock has traded on average 681.38K shares per day over the past 3-months and 590060 shares per day over the last 10 days, according to various share statistics. A total of 63.35M shares are outstanding, with a floating share count of 62.21M. Insiders hold about 1.79% of the company’s shares, while institutions hold 105.26% stake in the company. Shares short for BPMC as of 1723680000 were 4054068 with a Short Ratio of 5.95, compared to 1721001600 on 4785197. Therefore, it implies a Short% of Shares Outstanding of 4054068 and a Short% of Float of 7.21.
